<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02555449</url>
  </required_header>
  <id_info>
    <org_study_id>15566</org_study_id>
    <secondary_id>I7X-EW-LLCC</secondary_id>
    <nct_id>NCT02555449</nct_id>
  </id_info>
  <brief_title>A Study of [¹⁴C]-LY3202626 in Healthy Male Participants</brief_title>
  <official_title>Disposition of [¹⁴C]-LY3202626 Following Oral Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure how much of the specially prepared study drug,&#xD;
      LY3202626, containing radiolabeled carbon [¹⁴C] gets into the blood stream and how long it&#xD;
      takes the body to get rid of it.&#xD;
&#xD;
      Information about any side effects that may occur will also be collected.&#xD;
&#xD;
      Participants will stay at a clinical research unit (CRU). The study will last about 28 days&#xD;
      (check in to follow-up) for each participant.&#xD;
&#xD;
      This study is for research purposes only and is not intended to treat any medical condition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fecal Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</measure>
    <time_frame>Predose, 6, 12, 24, 48, 72 Hours At 24 Hour Intervals Until Release Criteria Met</time_frame>
    <description>Fecal excretion of radioactivity over time expressed as a percentage of the total radioactive dose administered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</measure>
    <time_frame>Predose, 6, 12, 24, 48, 72 Hours At 24 Hour Intervals Until Release Criteria Met</time_frame>
    <description>Urinary excretion of radioactivity over time was expressed as a percentage of the total radioactive dose administered</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Radioactivity Pharmacokinetics Maximum Observed Concentration (Cmax)</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 Hours At 24 Hour Intervals Until Release Criteria Met</time_frame>
    <description>Plasma radioactivity pharmacokinetics were measured by the maximum observed concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Radioactivity Pharmacokinetics Area Under the Concentration-time Curve From Time Zero to Infinity (AUC[0-∞])</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 Hours At 24 Hour Intervals Until Release Criteria Met</time_frame>
    <description>Plasma radioactivity pharmacokinetics were measured by the area under the concentration-time curve from time zero to infinity (AUC[0-∞]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Radioactivity Pharmacokinetics Area Under the Concentration-time Curve From Time Zero to the Last Timepoint With a Measurable Concentration (AUC[0-tlast])</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 Hours At 24 Hour Intervals Until Release Criteria Met</time_frame>
    <description>Plasma radioactivity pharmacokinetics were measured by the area under the concentration-time curve from time zero to the last timepoint with a measurable concentration (AUC[0-tlast]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Metabolites Representing at Least 10% of the Total Radioactivity in Plasma</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24 Hours Postdose</time_frame>
    <description>Total number of metabolites were identified in at least 10% of the total radioactivity in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Metabolites in Excreta (Urine and Feces) That Represent at Least 10% of the Dose of Radioactivity</measure>
    <time_frame>From Dosing Until Release Criteria Is Met</time_frame>
    <description>The total number of metabolites identified in excreta (urine and feces) that represent at least 10% of the dose of radioactivity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>[¹⁴C]-LY3202626</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of LY3202626 containing 100 micro curies of radioactivity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[¹⁴C]-LY3202626</intervention_name>
    <description>Administered as solution by mouth</description>
    <arm_group_label>[¹⁴C]-LY3202626</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy males, as determined by physical examination, clinical laboratory&#xD;
             tests, medical history and electrocardiogram (ECG)&#xD;
&#xD;
          -  Have a body mass index (BMI) of 18.5 to 32.0 kilograms per meter squared (kg/m²)&#xD;
             inclusive at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have participated in a [¹⁴C]-study within the last 6 months prior to admission for&#xD;
             this study&#xD;
&#xD;
          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug&#xD;
             screening&#xD;
&#xD;
          -  Have consumed grapefruits or grapefruit-containing products, Seville oranges or&#xD;
             Seville orange-containing products, star fruits or star fruit-containing products&#xD;
             within 7 days prior to dosing or intend to consume during the study&#xD;
&#xD;
          -  Have a history of constipation or have had acute constipation within 3 weeks prior to&#xD;
             admission&#xD;
&#xD;
          -  Are currently or have been smokers or users of tobacco or nicotine replacement&#xD;
             products within the 3 months prior to admission and/or have positive cotinine at&#xD;
             screening or check-in&#xD;
&#xD;
          -  Exposure to significant diagnostic, therapeutic, or employment-related radiation&#xD;
             within 12 months prior to dosing (e.g., serial x-ray or computed tomography scans,&#xD;
             barium meal, current employment in a job requiring radiation exposure monitoring)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 17, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2015</study_first_posted>
  <results_first_submitted>March 22, 2021</results_first_submitted>
  <results_first_submitted_qc>March 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2021</results_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>[¹⁴C]-LY3202626</title>
          <description>Single 10 milligram (mg) oral dose of LY3202626 containing 100 micro curies of radioactivity</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants</population>
      <group_list>
        <group group_id="B1">
          <title>[¹⁴C]-LY3202626</title>
          <description>Single oral dose of LY3202626 containing (10 milligrams) 100 micro curies of radioactivity</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.7" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.40" spread="6.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Kilogram/Square Meter (kg/m²)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.90" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fecal Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</title>
        <description>Fecal excretion of radioactivity over time expressed as a percentage of the total radioactive dose administered.</description>
        <time_frame>Predose, 6, 12, 24, 48, 72 Hours At 24 Hour Intervals Until Release Criteria Met</time_frame>
        <population>All participants who received the study drug and have evaluable pharmacokinetics (PK) data.</population>
        <group_list>
          <group group_id="O1">
            <title>[¹⁴C]-LY3202626</title>
            <description>Single 10-mg oral dose of LY3202626 containing approximately 100 microcuries of [14C]-LY3202626.</description>
          </group>
        </group_list>
        <measure>
          <title>Fecal Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</title>
          <description>Fecal excretion of radioactivity over time expressed as a percentage of the total radioactive dose administered.</description>
          <population>All participants who received the study drug and have evaluable pharmacokinetics (PK) data.</population>
          <units>percentage of the total radioactive dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" spread="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinary Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</title>
        <description>Urinary excretion of radioactivity over time was expressed as a percentage of the total radioactive dose administered</description>
        <time_frame>Predose, 6, 12, 24, 48, 72 Hours At 24 Hour Intervals Until Release Criteria Met</time_frame>
        <population>All participants who received the study drug and have evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>[¹⁴C]-LY3202626</title>
            <description>Single 10-mg oral dose of LY3202626 containing approximately 100 microcuries of [14C]-LY3202626.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</title>
          <description>Urinary excretion of radioactivity over time was expressed as a percentage of the total radioactive dose administered</description>
          <population>All participants who received the study drug and have evaluable PK data.</population>
          <units>percentage of the total radioactive dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Radioactivity Pharmacokinetics Maximum Observed Concentration (Cmax)</title>
        <description>Plasma radioactivity pharmacokinetics were measured by the maximum observed concentration (Cmax).</description>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 Hours At 24 Hour Intervals Until Release Criteria Met</time_frame>
        <population>All participants who received the study drug and have evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>[¹⁴C]-LY3202626</title>
            <description>Single 10-mg oral dose of LY3202626 containing approximately 100 microcuries of [14C]-LY3202626.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Radioactivity Pharmacokinetics Maximum Observed Concentration (Cmax)</title>
          <description>Plasma radioactivity pharmacokinetics were measured by the maximum observed concentration (Cmax).</description>
          <population>All participants who received the study drug and have evaluable PK data.</population>
          <units>nanogram/millilter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Radioactivity Pharmacokinetics Area Under the Concentration-time Curve From Time Zero to Infinity (AUC[0-∞])</title>
        <description>Plasma radioactivity pharmacokinetics were measured by the area under the concentration-time curve from time zero to infinity (AUC[0-∞]).</description>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 Hours At 24 Hour Intervals Until Release Criteria Met</time_frame>
        <population>All participants who received the study drug and have evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>[¹⁴C]-LY3202626</title>
            <description>Single 10-mg oral dose of LY3202626 containing approximately 100 microcuries of [14C]-LY3202626.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Radioactivity Pharmacokinetics Area Under the Concentration-time Curve From Time Zero to Infinity (AUC[0-∞])</title>
          <description>Plasma radioactivity pharmacokinetics were measured by the area under the concentration-time curve from time zero to infinity (AUC[0-∞]).</description>
          <population>All participants who received the study drug and have evaluable PK data.</population>
          <units>nanogram*hour/millilter (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1120" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Radioactivity Pharmacokinetics Area Under the Concentration-time Curve From Time Zero to the Last Timepoint With a Measurable Concentration (AUC[0-tlast])</title>
        <description>Plasma radioactivity pharmacokinetics were measured by the area under the concentration-time curve from time zero to the last timepoint with a measurable concentration (AUC[0-tlast]).</description>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 Hours At 24 Hour Intervals Until Release Criteria Met</time_frame>
        <population>All participants who received the study drug and have evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>[¹⁴C]-LY3202626</title>
            <description>Single 10-mg oral dose of LY3202626 containing approximately 100 microcuries of [14C]-LY3202626.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Radioactivity Pharmacokinetics Area Under the Concentration-time Curve From Time Zero to the Last Timepoint With a Measurable Concentration (AUC[0-tlast])</title>
          <description>Plasma radioactivity pharmacokinetics were measured by the area under the concentration-time curve from time zero to the last timepoint with a measurable concentration (AUC[0-tlast]).</description>
          <population>All participants who received the study drug and have evaluable PK data.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="814" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Metabolites Representing at Least 10% of the Total Radioactivity in Plasma</title>
        <description>Total number of metabolites were identified in at least 10% of the total radioactivity in plasma.</description>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24 Hours Postdose</time_frame>
        <population>All participants who received the study drug and have evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>[¹⁴C]-LY3202626</title>
            <description>Single 10-mg oral dose of LY3202626 containing approximately 100 microcuries of [14C]-LY3202626.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Metabolites Representing at Least 10% of the Total Radioactivity in Plasma</title>
          <description>Total number of metabolites were identified in at least 10% of the total radioactivity in plasma.</description>
          <population>All participants who received the study drug and have evaluable PK data.</population>
          <units>metabolites</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Metabolites in Excreta (Urine and Feces) That Represent at Least 10% of the Dose of Radioactivity</title>
        <description>The total number of metabolites identified in excreta (urine and feces) that represent at least 10% of the dose of radioactivity</description>
        <time_frame>From Dosing Until Release Criteria Is Met</time_frame>
        <population>All participants who received the study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>[¹⁴C]-LY3202626</title>
            <description>Single 10-mg oral dose of LY3202626 containing approximately 100 microcuries of [14C]-LY3202626.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Metabolites in Excreta (Urine and Feces) That Represent at Least 10% of the Dose of Radioactivity</title>
          <description>The total number of metabolites identified in excreta (urine and feces) that represent at least 10% of the dose of radioactivity</description>
          <population>All participants who received the study drug and had evaluable PK data.</population>
          <units>metabolites</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Baseline through End of Study (Up to 2 Months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>[¹⁴C]-LY3202626</title>
          <description>Single 10 mg oral dose of LY3202626 containing 100 micro curies of radioactivity</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

